[1]
|
E. B. Andrews and R. D. Mann, “Pharmacovigilance,” 2nd Edition, John Wiley & Sons, Chichester, 2007.
|
[2]
|
W. H. Wardell, G. P. Velo and N. M, Jarocha, “Drug Development, Regulatory Assessment and Post Marketing Surveillance,” Plenum, New York, 1981.
|
[3]
|
S. Olsson, “The Role of the WHO Programme on International Drug Monitoring in Coordination Worldwide Drug Safety Efforts,” Drug Safety, Vol. 19, No. 1, 1998, pp. 1-10. doi:10.2165/00002018-199819010-00001
|
[4]
|
Ministerium für Gesundheitswesen. Arbeitsgruppe für Organisation und Inspektion beim Ministerrat, Kontrolab- teilung. Bericht über Stand und erforderliche Massnahmen zur weiteren Erh?hung der Arzneimittelsicherheit in der DDR. Pharmazie und Technik. Berlin, 1984.
|
[5]
|
J. Richter and M. Wolski, “40 Jahre Regelung und überwa Chung des Arzneitmittelverkehrs in der Deutschen Demokratischen Republik,” Pharmazie, Vol. 44, No. 10, 1989, pp. 666-671.
|
[6]
|
M. B?hm, K. Gerccke, L. Kny, H. Probst and J. Richter, 45 Jahre Pharmazie in Deutschland Ost. 7bDirekt Apo- thekenservice AG, Fürstenfeldbruck, Berlin, 2007.
|
[7]
|
J. Richter, H. J. Seidelin, M. B?hm, H. G. Keune and E. Gueinzius, “Arzneimittelund Apothekenrecht der Republic,” Akademie-Verlag, Berlin, 1985.
|
[8]
|
The Medical Dictionary for Regulatory Activities (MedDRA). http://www.meddramsso.com
|
[9]
|
L. Aagaard, L. H. Nielsen and E. H. Hansen, “Consumer Reporting of Adverse Drug Reactions: A Retrospective Analysis of the Danish Adverse Drug Reaction Database from 2004 to 2006,” Drug Safety, Vol. 32, No. 11, 2009, pp. 1067-1074. doi:10.2165/11316680-000000000-00000
|
[10]
|
J. de Langen, F. van Hunsel, A. Passier, L. de Jong-van den Berg, K. van Grootheest, “Adverse Drug Reaction Reporting by Patients in the Netherlands: Three Years of Experience,” Drug Safety, Vol. 31, No. 6, 2008, 515-524.
doi:10.2165/00002018-200831060-00006
|